<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719001</url>
  </required_header>
  <id_info>
    <org_study_id>PT1802</org_study_id>
    <nct_id>NCT03719001</nct_id>
  </id_info>
  <brief_title>Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study</brief_title>
  <official_title>A Pilot Study to Evaluate the Effect of Changing Physiological Conditions on the Amplitude and/or Frequency of Myogenic Oscillations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous myogenic oscillations will be studied under general anesthesia using finger
      photoplethysmography. This pilot study will explore potential physiological conditions that
      will effect the amplitude and/or frequency of myogenic oscillations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, nonrandomized, nonblinded, interventional clinical pilot research
      study that plans to enroll 40 patients.

      Study will be conducted while subjects are under general anesthesia.

      Myogenic oscillations will be measured using finger photoplethysmography. Changes in the
      amplitude and/or frequency of these oscillations will be analyzed in response to the
      interventions. Arterial blood pressure will be recorded to verify the efficacy of the
      interventions.

      Six different interventions that will either lower or increase blood pressure will be applied
      to the subjects. Each subject will receive 1 or 2 of the six interventions. Each of the 6
      interventions will be applied to 8 subject.

      The interventions that the subject will not be randomized. They will be determined by the
      subjects blood pressure immediately before the intervention to guarantee that the blood
      pressure manipulations are within a safe range.

      Data will be analyzed offline using Matlab.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>myogenic oscillations</measure>
    <time_frame>up to 5 minutes</time_frame>
    <description>change in amplitude and/of frequency of myogenic oscillations</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clevidipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clevidipine infusion will be used to increase blood pressure by 20 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Chloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tetanic stimulus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Increased venous pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure</description>
    <arm_group_label>Phenylephrine</arm_group_label>
    <other_name>Neosynephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevidipine</intervention_name>
    <description>blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca</description>
    <arm_group_label>Clevidipine</arm_group_label>
    <other_name>Cleviprex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tetanic stimulus</intervention_name>
    <description>A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)</description>
    <arm_group_label>tetanic stimulus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Increased venous pressure</intervention_name>
    <description>A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.</description>
    <arm_group_label>Increased venous pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Chloride</intervention_name>
    <description>CaCl will be administered to increase blood pressure and plasma calcium concentration</description>
    <arm_group_label>Calcium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 18 yrs of age

          2. Undergoing surgery in Moffitt-Long operating rooms

          3. Receiving general anesthesia

          4. Will have an intra-arterial catheter for clinical purposes

          5. Able to consent in english

        Exclusion Criteria:

          1. Under 18 years of age

          2. unable to provide informed consent

          3. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pekka Talke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Pekka Talke</investigator_full_name>
    <investigator_title>Professor Emeritus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clevidipine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

